Tas Faruk, Erturk Kayhan
Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul 34390, Turkey.
Mol Clin Oncol. 2017 Dec;7(6):1083-1088. doi: 10.3892/mco.2017.1439. Epub 2017 Oct 4.
Patient age has been reported as a highly significant and strong predictor of the outcome in patients with cutaneous melanoma. The aim of the present study was to determine the clinical significance of patient age in Turkish patients with cutaneous melanoma. A total of 1,169 patients with pathologically proven cutaneous melanoma were enrolled. Age of patients was classified as young (<40 years), middle-aged (40-59 years) and old (≥60 years). The median age of the patients was 51 years (range, 16-104 years). Non-superficial spreading histology was significantly more observed in old patients than in the other age groups (P<0.001). A lower Clark invasion level was significantly more observed in young patients compared with the other age groups (P=0.013) and higher levels were significantly more observed in older patients compared with the other age groups (P=0.002). Furthermore, the rate of thin Breslow depth was significantly higher in young patients compared with others (P=0.038). Although a lower mitotic rate was observed predominantly in young patients compared with others (P=0.007), ulceration was significantly more present in older patients (P<0.001) and absent in the young patients (P=0.003). Patient age was not significantly associated with relapse-free survival (P=0.327), whereas a significant correlation was demonstrated for overall survival (OS) (P=0.007). The old patients had poorer survival compared with the other ages (P=0.009 for young patients and P=0.012 for middle-aged patients). However, patient age did not remain significant for OS in multivariate analysis (P=0.768). In conclusion, although patient age does not have a significant predictive role on nodal involvement, recurrence and metastasis, an age of ≥60 years may be associated with more aggressive histological features and poorer outcome in patients with cutaneous melanoma.
据报道,患者年龄是皮肤黑色素瘤患者预后的一个高度显著且有力的预测指标。本研究的目的是确定患者年龄在土耳其皮肤黑色素瘤患者中的临床意义。共纳入1169例经病理证实的皮肤黑色素瘤患者。患者年龄分为年轻(<40岁)、中年(40 - 59岁)和老年(≥60岁)。患者的中位年龄为51岁(范围16 - 104岁)。老年患者中观察到非浅表扩散组织学的比例显著高于其他年龄组(P<0.001)。与其他年龄组相比,年轻患者中观察到较低的克拉克浸润水平的比例显著更高(P = 0.013),而老年患者中观察到较高浸润水平的比例显著高于其他年龄组(P = 0.002)。此外,年轻患者中薄的 Breslow 深度的比例显著高于其他患者(P = 0.038)。虽然与其他患者相比,年轻患者中观察到的有丝分裂率较低(P = 0.007),但溃疡在老年患者中显著更常见(P<0.001),在年轻患者中不存在(P = 0.003)。患者年龄与无复发生存率无显著相关性(P = 0.327),而与总生存期(OS)有显著相关性(P = 0.007)。老年患者的生存率低于其他年龄组(年轻患者P = 0.009,中年患者P = 0.012)。然而,在多变量分析中,患者年龄对OS不再具有显著性(P = 0.768)。总之,虽然患者年龄对淋巴结受累、复发和转移没有显著的预测作用,但≥60岁的年龄可能与皮肤黑色素瘤患者更具侵袭性的组织学特征和更差的预后相关。